...
首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Increasing the binding affinity of VEGFR-2 inhibitors by extending their hydrophobic interaction with the active site: Design, synthesis and biological evaluation of 1-substituted-4-(4-methoxybenzyl) phthalazine derivatives
【24h】

Increasing the binding affinity of VEGFR-2 inhibitors by extending their hydrophobic interaction with the active site: Design, synthesis and biological evaluation of 1-substituted-4-(4-methoxybenzyl) phthalazine derivatives

机译:通过扩展其与活性位点的疏水性相互作用来提高VEGFR-2抑制剂的结合亲和力:1-取代的4-(4-甲氧基苄基)酞嗪衍生物的设计,合成和生物学评估

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

A series of anilinophthalazine derivatives 4a-j was initially synthesized and tested for its VEGFR-2 inhibitory activity where it showed promising activity (IC50 = 0.636-5.76 mu M). Molecular docking studies guidance was used to improve the binding affinity for series 4a-j towards VEGFR-2 active site. This improvement was achieved by increasing the hydrophobic interaction with the hydrophobic back pocket of the VEGFR-2 active site lined with the hydrophobic side chains of Ile888, Leu889, Ile892, Val898, Val899, Leu1019 and Ile1044. Increasing the hydrophobic interaction was accomplished by extending the anilinophthalazine scaffold with a substituted phenyl moiety through an uriedo linker which should give this extension the flexibility required to accommodate itself deeply into the hydrophobic back pocket. As planned, the designed uriedo-anilinophthalazines 7a-i showed superior binding affinity than their anilinophthalazine parents (IC50 = 0.083-0.473 mu M). In particular, compounds 7g-i showed IC50 of 0.086, 0.083 and 0.086 mu M, respectively, which are better than that of the reference drug sorafenib (IC50 = 0.09 mu M). (C) 2016 Elsevier Masson SAS. All rights reserved.
机译:最初合成了一系列苯并酞菁衍生物4a-j,并测试了其对VEGFR-2的抑制活性,并显示出有希望的活性(IC50 = 0.636-5.76μM)。分子对接研究指南用于提高系列4a-j对VEGFR-2活性位点的结合亲和力。通过增加与衬有Ile888,Leu889,Ile892,Val898,Val899,Leu1019和Ile1044的疏水性侧链的VEGFR-2活性位点的疏水性后口袋的疏水性相互作用,实现了这一改进。疏水相互作用的增加是通过将带有取代的苯基部分的苯胺基酞嗪支架通过脲醛酸酯连接基延伸而实现的,该骨架应赋予该延伸基以所需的柔性,以使其自身深深地容纳在疏水性后袋中。按照计划,设计的尿酸-苯胺基酞菁7a-i的结合亲和力比其苯胺基酞嗪母体优越(IC50 = 0.083-0.473μM)。特别地,化合物7g-i显示出IC 50分别为0.086、0.083和0.086μM,这优于参考药物索拉非尼的IC 50(IC 50 =0.09μM)。 (C)2016 Elsevier Masson SAS。版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号